Previous Investigations
Other Litigations Vioxx Research Center News & Warnings
|
What You Should Know - Transcript From the FDA Meeting on Pain Med Vioxx
Your Vioxx lawyer provides you the complete transcript of the February 16th, 2005 joint meeting of the FDA's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. We have formatted the complete transcript of the three day conference for easy navigation to provide you with the best possible Vioxx information. To contact a Vioxx Lawyer, click here for a FREE case evaluation.
Contents:
Call to Order:
Alastair J. Wood, M.D., Chair
Conflict of Interest
Statement:
Kimberly Littleton Topper, M.S.,
Welcome:
Steven Galson, M.D., MPH
Regulatory History
Jonca Bull, M.D.
Gastrointestinal Effects
of NSAIDs and COX-2 Specific Inhibitors
Byron Cryer, M.D.,
Mechanism Based Adverse
Cardiovascular Events and Specific Inhibitors of COX-2
Garret
FitzGerald,
Committe Questions to Speakers
Sponsor Presentation:
Vioxx (Rofecoxib),
Peter S. Kim, M.D.
Ned S. Braunstein,
M.D.
FDA Presentation: Vioxx
(Rofecoxib),
Lourdes Villalba, M.D.,
Committee Questions to the Speakers
Sponsor
Presentation: Celebrex (Celecoxib),
Joseph M. Feczko, M.D.
Cardiac Safety and
Risk/Benefit Assessment of Celecoxib
Kenneth M. Verburg, Ph.D.
FDA Presentation: COX-2
CV Safety: Celecoxib,
James Witter, M.D., Ph.D.,
NIH and Investigator
Presentation: Celecoxib in Adenoma Prevention Trials: The APC Trial (Prevention
of Sporadic Colorectal Adenomas with Celecoxib)
Ernest Hawk,
M.D.
NIH Investigator
Presentation: The PreSAP Trial (Prevention of Colorectal Sporadic Adenomatous
Polyps)
Bernard Levin, M.D.
Committee Questions to Speakers
Sponsor Presentation:
Cardiovascular Safety and Risk/Benefit Assessment of Valdecoxib and Parecoxib
Kenneth M. Verburg, Ph.D.
Concluding Comments
Joseph M. Feczko, M.D.
FDA Presentation: COX-2
CV Safety: Valdecoxib-Parecoxib,
James Witter, M.D., Ph.D.
Bayer and Roche Joint
Presentation on Naproxen,
Leonard M. Baum, R.Ph.
Safety Data
Martin H. Huber, M.D.
Committee Questions to Speakers
If you or a loved one has been injured by a cox-2 specific inhibitor such as Bextra, Celebrex or Vioxx, please fill out our FREE case evaluation form. A Client Relations Representative will contact you shortly to discuss your potential case. Feel free as well to call us at (800) 476-6070 or email us at clientrelations@weitzlux.com
Weitz & Luxenberg is no longer accepting Vioxx cases.
see also:
Cardio Events & COX-2
Your Vioxx Lawyer - Vioxx, Celebrex & Bextra FDA Transcript - Cardiovascular Events, COX-2Your Vioxx lawyer provides the complete transcript of the FDA meeting.
Bayer/Roche: Naproxen
Your Vioxx Lawyer - Vioxx, Celebrex & Bextra FDA Transcript - Bayer, Roche: NaproxenYour Vioxx lawyer provides the complete transcript of the FDA meeting.
More Merck Losses
Merck Insurance Carriers Jump Ship Over Vioxx LossesMerck Insurance Carriers Jump Ship Over Vioxx Defense Costs & Losses
